| Revenue growth | Revenue de-grew 5% YoY to ₹904cr due to business restructuring. |
|---|---|
| Margins | Gross margins improved to 70% from 66% following generic business exit. |
| Demand visibility | Strong for chronic brands; West Asia demand hit by shipping issues. |
| Management confidence | Balanced; focused on integration synergies despite temporary operational slowdown. |
Growth
Branded business grew 8% while chronic segments surged 19%, significantly outperforming market growth despite consolidated revenue pressures.
Outlook
Management expects double-digit India growth and single-digit international recovery starting Q2 FY27 as integration synergies materialize.
Risks
Integration friction, high employee attrition at JB, and West Asia shipping disruptions remain key near-term execution hurdles.
Earnings Call filed with BSE, NSE: JBCHEPHARM. Summary written with AI assistance from the document.
More from J B Chemicals & Pharmaceuticals Ltd
All →J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
Q4 FY26 marked an operational reset following Torrent Pharma's acquisition of a controlling stake. Management focused on integration, distribution optimization, and rationalizing low-margin trade generics.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
Q4 FY26 shows operational reset post Torrent Pharma acquisition; revenue at ₹904cr (down 5% YoY) with adjusted EBITDA margin improving to 27%.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
This was an operational reset quarter following Torrent Pharma's acquisition, marked by intentional portfolio pruning and alignment of trade practices with the new parent entity.
JB Chemicals & Pharmaceuticals Q4 FY26 Results: Net Profit ₹101.4 Cr, Down 30.4% YoY
JB Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹904.2 Cr (-4.8% YoY) and net profit of ₹101.4 Cr (-30.4% YoY) for Q4 FY26.
- Key figure
- Net profit ₹101.4 Cr · -30.4% YoY